Chimerix Q2 2024 GAAP EPS $(0.23), Inline, Sales $129.000K Beat $62.500K Estimate
Portfolio Pulse from Benzinga Newsdesk
Chimerix (NASDAQ:CMRX) reported Q2 2024 GAAP EPS of $(0.23), in line with estimates, and sales of $129 million, significantly beating the $62.5 million estimate. Sales increased by 396.15% year-over-year.
August 13, 2024 | 11:05 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Chimerix reported Q2 2024 GAAP EPS of $(0.23), in line with estimates, and sales of $129 million, significantly beating the $62.5 million estimate. Sales increased by 396.15% year-over-year.
The in-line EPS and significant sales beat, along with a substantial year-over-year sales increase, are likely to positively impact Chimerix's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100